Motilal Oswal and Invascent acquired Symbiotec from Actis.

Motilal Oswal and Invascent, two Indian financial services companies, acquired Symbiotec, a pharmaceutical company, from Actis. Financial terms were not disclosed. Mr. Vishal Tulsyan, ManagingDirector and CEO of MOPE commented, “Indianpharmaceutical companies continue to gain market share and credibilityworldwide. At MOPE, pharmaceuticals is one of our focus sectors and we continueto look for attractive investment opportunities therein. We are pleased to announceour investment in Symbiotec that presents a unique opportunity to partner withone of the largest vertically integrated company in the niche segment ofsteroids and hormones. Through this partnership, we intend to help Symbiotecachieve its vision of becoming an integrated “farm to pharmacy” company”.